Opendata, web and dolomites

Cenya SIGNED

Ex vivo cell labelling for in vivo imaging applied to cell therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Cenya project word cloud

Explore the words cloud of the Cenya project. It provides you a very rough idea of what is the project "Cenya" about.

direct    exclusively    trafficking    therapy    magic    therapeutics    approval    cancer    lower    safety    size    labelling    cells    validation    hired    fallen    medicine    trials    individual    ex    heart    diseased    inhibitors    nanoparticle    decide    tracking    bedside    gmp    monitor    multiscale    40    hurdles    bench    outlined    necessitating    clinical    unbelievable    track    tissue    lack    venture    gene    imaging    licensing    advent    stem    commercial    diagnose    made    seeing    push    investment    infusion    vivo    car    market    np    preclinical    agents    degree    simpler    faster    therapies    monitoring    noninvasive    curing    opportunity    ready    optimise    annum    possess    while    nearly    repopulating    300m    expectations    play    patients    good    labelled    academics    sometimes    recruited    fda    drive    lymphocyte    cell    data    ceo    industry    modern    treatments    biodistribution    techniques    disease    day    optimisation    surveyed    deal    attractive    staff    cenya    suitable    nps    regulatory    cheaper    checkpoint    advisors    time    transferred   

Project "Cenya" data sheet

The following table provides information about the project.

Coordinator
CENYA IMAGING B.V. 

Organization address
address: TWEEDE KOSTVERLORENKADE 11H
city: AMSTERDAM
postcode: 1052RK
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENYA IMAGING B.V. NL (AMSTERDAM) coordinator 150˙000.00

Map

 Project objective

While we do not possess magic, modern day medicine can sometimes approach the unbelievable - curing cancer or repopulating diseased heart tissue; all possible due to the advent of cell therapy. However, cell therapy has fallen far short of expectations. Its success requires the ability to monitor and optimise treatments in real time for each individual; necessitating a direct means of monitoring transferred cells. Noninvasive imaging techniques are essential to the success of modern therapeutics. Here, I will build on my work on developing multiscale GMP-ready imaging nanoparticle (NP) agents with the objective of out-licensing the technology to a new commercial venture, Cenya Imaging, to take this work from the bench to the bedside, and I have recruited an experienced CEO to drive this forward. Advisors have outlined a cheaper, faster and simpler path to regulatory approval for Cenya NPs: labelling cells ex vivo and tracking labelled cells after infusion into patients; since, with this approach, Cenya NPs are used to only track cells and not diagnose a disease, the regulatory hurdles are far lower. Recent developments in cell therapeutics have made tracking of cells a very attractive market; specifically (1) increasing investment in CAR-T cells, checkpoint inhibitors (which affect lymphocyte trafficking), and stem cell therapies (40% per annum growth in phase I trials); (2) regulatory push for increased safety and biodistribution data in trials; and (3) a lack of suitable clinical imaging agents. Market size is estimated at €300M; the FDA recently hired 50 new staff exclusively to deal with cell and gene therapies. We will exploit this new market, while also seeing this as the opportunity to play a significant role in the optimisation of cell therapies. We have surveyed nearly 100 users of cell therapy (preclinical, clinical; academics and industry) to decide on our approach, providing a good degree of validation for our choice of focus.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CENYA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CENYA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More